Redefining quality--implications of recent clinical trials.
Krumholz
Harlan M
HM
Yale University School of Medicine, New Haven, CT, USA.
Lee
Thomas H
TH
D000924:Anticholesteremic Agents / Q000009:adverse effects; D002318:Cardiovascular Diseases / Q000517:prevention & control; D002986:Clinical Trials as Topic / Q000592:standards*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D011787:Quality of Health Care; D011804:Quinolines / Q000009:adverse effects; D012307:Risk Factors
D000924:Anticholesteremic Agents; D007004:Hypoglycemic Agents; D011804:Quinolines; C483909:torcetrapib